Selvita S.A. entered a strategic initiative to significantly expand its services portfolio and enter the field of biologic drug discovery and development, adding comprehensive therapeutic antibody discovery and development capabilities.
 
The company will employ a team of experts specializing in the discovery and development of therapeutic antibodies and rent fully equipped state-of-the-art laboratories.
 
Selvita will offer a suite of fully comprehensive antibody-related services for therapeutic antibody discovery, and will open a new research site in Wroclaw, Poland, where it will rent over 400 square meters of state-of-the-art labs along with all necessary infrastructure. The company has also already secured the equipment required to conduct antibody discovery-related research studies. Selvita plans to initially contract 16 highly experienced scientists, formerly at Pure Biologics, specializing in antibody engineering. The intention of the company is to double the headcount within the next 3 years.
 
Milosz Gruca, PhD, Chief Commercial Officer and Executive VP at Selvita said, “We are thrilled to announce the expansion of our services portfolio with a comprehensive range of capabilities dedicated to the discovery and development of antibody-based drugs. Leveraging the state-of-the-art research infrastructure and exceptional team of scientists at our Wroclaw site, we are poised to deliver highly sought-after capabilities to our clients.”
 
Selvita augments existing portfolio of discovery and development services in small molecules. The new services for biologics complement Selvita’s current offerings in the production of recombinant proteins and a comprehensive suite of structural biology services, including the production of recombinant antibodies in various formats, antibody chimerization, engineering of bispecific antibodies, isotype switching, and a range of mAbs-based assays.